Vascular Biogenics Ltd. - Ordinary Shares (VBLT) Company Bio
Vascular Biogenics Limited is a clinical-stage biopharmaceutical company focusing on the discovery, development, and commercialization of treatments for cancer and immune-inflammatory diseases. The company was founded in 2000 and is based in Or Yehuda, Israel.
VBL Therapeutics ([[VBLT]]) Q2 results:Revenues: $0.2M (+14.3%).Net loss: ($5.8M) (-23.4%); loss/share: ($0.14) (-7.7%).Cash used in operations: ($12.6M) (-137.7%).The investigator sponsored studies of VB-111 in GBM and colorectal cancer are headed for initiation.Yesterday, The independent Data Safety Monitoring Committee completed second interim analysis of OVAL Phase 3 study of VB-111 in...
The views expressed are her own.) As U.S. coronavirus cases hit records and reopenings are dialled back, Federal Reserve officials admitted economic growth forecasts from the June policy meeting did not factor in the risk of a second wave. Fed Governor Lael Brainard summed it up as "a thick fog of uncertainty" and said "downside risks predominate." A similar message from the corporate world -- Delta Airlines CEO Ed Bastian said the industry was "at a stall right now."
VBL Therapeutics (Nasdaq: VBLT) today presented a late-breaking study showing that its proprietary MOSPD2 bi-specific antibody candidates induced T-cell activation and significantly extended the survival of animals carrying established metastatic cervical and breast cancer (p=0.001; p=0.002). Data are presented today at the American Association for Cancer Research (AACR) Virtual Annual Meeting II, being held June 22–24, 2020.